Alumis Inc (ALMS)

Currency in USD
11.45
+0.27(+2.42%)
Closed·
11.450.00(0.00%)
·
ALMS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.0311.55
52 wk Range
2.7612.44
Key Statistics
Prev. Close
11.18
Open
11.08
Day's Range
11.03-11.55
52 wk Range
2.76-12.44
Volume
644.71K
Average Volume (3m)
973.84K
1-Year Change
36.8%
Book Value / Share
3.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALMS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.86
Upside
+73.42%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Alumis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Alumis Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Compare ALMS to Peers and Sector

Metrics to compare
ALMS
Peers
Sector
Relationship
P/E Ratio
−4.9x−4.4x−0.6x
PEG Ratio
−0.06−0.060.00
Price/Book
3.1x1.6x2.6x
Price / LTM Sales
54.0x5.0x3.2x
Upside (Analyst Target)
78.9%15.1%41.8%
Fair Value Upside
Unlock5.8%5.1%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 19.86
(+73.42% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy20.00+74.67%14.00Maintain18/12/2025
Morgan Stanley
Buy22.00+92.14%23.00Maintain15/08/2025
Cantor Fitzgerald
Buy---Maintain14/08/2025
H.C. Wainwright
Buy14.00+22.27%-Maintain25/07/2025
Wells Fargo
Buy17.00+48.47%-New Coverage25/07/2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-1.06 / --
Revenue / Forecast
2.07M / --
EPS Revisions
Last 90 days

Alumis (ALMS) Income Statement & Profits

People Also Watch

28.23
SEPN
-4.21%
9.22
ENGN
+5.13%
8.88
KYTX
+9.23%
32.20
MBX
-7.47%

FAQ

What Is the Alumis (ALMS) Share Price Today?

The live Alumis share price today is 11.45

What Stock Exchange Does Alumis (ALMS) Trade On?

Alumis is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Alumis?

The stock symbol (also called a 'ticker') for Alumis is "ALMS."

What Is the Current Alumis Market Cap?

As of today, Alumis market capitalisation is 1.17B.

What Is Alumis's (ALMS) Earnings Per Share (TTM)?

The Alumis EPS is currently -3.38 (Trailing Twelve Months).

When Is the Next Alumis Earnings Date?

Alumis's next earnings report will be released on 18 Nov 2025.

Is ALMS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Alumis moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alumis Stock Split?

Alumis has split 0 times. (See the ALMS stock split history page for full effective split date and price information.)

How Many Employees Does Alumis Have?

Alumis has 222 employees.

What is the current trading status of Alumis (ALMS)?

As of 24 Dec 2025, Alumis (ALMS) is trading at a price of 11.45, with a previous close of 11.18. The stock has fluctuated within a day range of 11.03 to 11.55, while its 52-week range spans from 2.76 to 12.44.

What Is Alumis (ALMS) Price Target According to Analysts?

The average 12-month price target for Alumis is USD19.85714, with a high estimate of USD25 and a low estimate of USD17. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +73.42% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.